Amneal Pharmaceuticals (AMRX) Delivers +37% Gains Over 30 Days on Earnings Momentum and Biosimilar Expansion
Key Takeaways
- Amneal Pharmaceuticals (AMRX) surged approximately 37% over the last 30 days, climbing from around $11.81 on May 19 to $16.21 as of June 18, 2026.
- The rally was fueled by a strong Q1 2026 earnings beat, the transformative $1.1 billion acquisition of Kashiv BioSciences, and multiple FDA approvals.
- Analyst sentiment turned decisively bullish, with Barclays raising its price target and UBS initiating coverage with a Buy rating and a $19 target.
- Positive interim Phase 4 ELEVATE-PD data for CREXONT in Parkinson's disease reinforced confidence in the company's specialty pipeline.
- Over the broader quarter, AMRX gained approximately 31%, reflecting sustained momentum across generics, biosimilars, and branded specialty segments.
Amneal Pharmaceuticals (AMRX) Company Overview and Market Position
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, that develops, manufactures, markets, and distributes a diversified portfolio of essential medicines. The company operates through three core segments: Affordable Medicines (generics, injectables, biosimilars, and a broad range of dosage forms), Specialty (branded pharmaceuticals focused on central nervous system and endocrine disorders, including Parkinson's disease treatments like Rytary and CREXONT), and AvKARE (pharmaceuticals, medical and surgical products primarily serving governmental agencies such as the Department of Defense and the Department of Veterans Affairs). With approximately 8,500 employees and operations spanning the United States, India, Ireland, and other international markets, Amneal has established itself as a significant player in the specialty and generic pharmaceutical industry. Investors follow AMRX closely due to its expanding biosimilar pipeline, growing specialty franchise, and strategic positioning in the rapidly evolving global generics market.
Amneal Pharmaceuticals (AMRX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AMRX shares delivered a remarkable rally, climbing from an adjusted closing price of $11.81 on May 19, 2026, to $16.21 by June 18, 2026 — a gain of approximately 37.3%. The move was characterized by several high-volume breakout sessions, including a 6.66% surge on June 11 and a 7.15% jump on June 9, reflecting intense institutional and retail buying interest. The stock briefly touched a 52-week high of $16.61 during this window before settling near the upper end of its range. I checked the technical setup using Tickeron’s AI Pattern Search Engine and the breakout signals aligned with the price action.
Zooming out to the full quarter, AMRX posted a gain of roughly 31%, extending a multi-month uptrend that began earlier in 2026. The quarterly performance was underpinned by the company's Q1 2026 earnings release in late April, which handily exceeded consensus estimates, and the announcement of the Kashiv BioSciences acquisition — a deal that reshaped the investment narrative around Amneal's long-term biosimilar growth trajectory. The stock's quarterly advance also reflected broader sector strength in specialty pharmaceuticals and growing investor appetite for companies with diversified revenue streams and visible pipeline catalysts.
What Drove AMRX Stock Price in the Last 30 Days
The 30-day surge in AMRX was propelled by a confluence of company-specific catalysts and favorable market dynamics. The most significant driver was the aftermath of Amneal's Q1 2026 earnings report, released in late April, which continued to resonate through May and June. The company reported adjusted diluted EPS of $0.27, far surpassing the consensus estimate of $0.17, while quarterly revenue of $722.52 million beat expectations of approximately $716.78 million. Management reaffirmed full-year 2026 guidance, projecting revenue between $3.05 billion and $3.15 billion and adjusted EBITDA of $740 million to $770 million, reinforcing confidence in the growth trajectory.
Equally transformative was the announced acquisition of Kashiv BioSciences in a cash-and-stock deal valued at up to $1.1 billion, which positions Amneal as a fully integrated global biosimilar leader. The deal, disclosed alongside preliminary Q1 results, significantly expanded the company's biosimilar pipeline and manufacturing capabilities, with management highlighting expected revenue and margin growth through 2030. This strategic move reshaped the long-term investment thesis and attracted fresh institutional attention.
On the regulatory front, Amneal received FDA approval for romidepsin injection solution — a ready-to-use formulation that offers a more convenient alternative to lyophilized powder requiring reconstitution, with 180 days of Competitive Generic Therapy market exclusivity. Additionally, the company announced positive interim results from its ongoing Phase 4 ELEVATE-PD study, reinforcing previously reported benefits of CREXONT in Parkinson's disease, including over three additional hours of daily "Good On" time when switching from RYTARY.
Analyst activity further amplified the rally. Barclays raised its price target on AMRX to $16 from $15 while maintaining an Overweight rating. UBS initiated coverage with a Buy rating and a $19 price target in mid-April, and the stock continued to benefit from the broader analyst consensus of Strong Buy with an average 12-month target of approximately $17.25. The combination of earnings momentum, M&A-driven strategic repositioning, regulatory wins, and bullish analyst sentiment created a powerful upward catalyst stack.
What Drove AMRX Stock Performance Over the Last Quarter
AMRX's quarterly performance of approximately 31% was shaped by a broader narrative of operational execution and strategic transformation. The Q1 2026 earnings beat served as the foundational catalyst, demonstrating that the company's diversified business model — spanning generics, specialty brands, and biosimilars — could deliver consistent above-consensus results. Revenue growth of 7.6% year-over-year on a trailing twelve-month basis and net income of $122.12 million underscored improving profitability after years of restructuring.
The Kashiv BioSciences acquisition, announced in late April, was the quarter's defining event. By bringing together Amneal's established commercial infrastructure and Kashiv's advanced biosimilar pipeline — including a proposed biosimilar to XOLAIR (omalizumab) with a Biologics License Application already submitted to the FDA — the deal created a clear pathway to becoming a top-tier biosimilar player. Investors responded favorably to the strategic logic and the potential for significant revenue and margin accretion through the end of the decade.
Additional quarterly catalysts included Amneal's addition to the S&P SmallCap 600 Index, which boosted passive fund inflows and institutional visibility. The company also launched its first two respiratory metered-dose inhalation products in the U.S. market, expanded its Parkinson's disease franchise with growing CREXONT adoption, and secured multiple FDA approvals across its generics portfolio. These developments, combined with a favorable macroeconomic backdrop for healthcare and specialty pharma, sustained the stock's upward momentum throughout the quarter.
Using Tickeron’s Trending AI Robots for Additional Market Perspective
In my own research process, I often review Tickeron’s Trending AI Robots page to see how automated strategies are performing across various tickers and market conditions. This section highlights a curated selection of top-performing AI-driven trading bots from a platform that hosts hundreds of automated strategies trading across thousands of tickers. These bots employ diverse methodologies — ranging from short-term technical pattern recognition to longer-term fundamental and momentum-based approaches — and are designed to adapt to evolving market conditions. Only the most relevant and consistently high-performing bots are featured, providing a streamlined view of strategies that have demonstrated real-time effectiveness. Each bot varies in strategy type, holding period, and performance metrics, allowing users to explore different approaches suited to their trading style. For those seeking data-driven insights and automated trading tools, exploring the Trending AI Robots page can offer a practical starting point.
AMRX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several key factors will shape AMRX's trajectory. The integration of Kashiv BioSciences and the advancement of its biosimilar pipeline — particularly the XOLAIR biosimilar candidate and other late-stage assets — will be critical milestones that investors should monitor closely. Progress toward regulatory submissions, FDA decisions, and commercial launch timelines will directly impact revenue projections and long-term valuation.
Amneal's next earnings report, estimated for early August 2026, will provide an important checkpoint on standalone performance and any updated guidance incorporating the Kashiv acquisition. Analysts will scrutinize CREXONT prescription trends, biosimilar revenue contributions, and margin expansion across the Affordable Medicines segment. Macroeconomic factors, including potential changes in drug pricing policy, FDA regulatory posture under the current administration, and interest rate movements affecting leveraged healthcare companies, also warrant attention. Competitive dynamics in the generics and biosimilars space — including moves by peers such as Viatris (VTRS), ANI Pharmaceuticals (ANIP), and Collegium Pharmaceutical (COLL) — will continue to influence sector sentiment and relative positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMRX in upward trend: 10-day moving average broke above 50-day moving average on June 03, 2026
The 10-day moving average for AMRX crossed bullishly above the 50-day moving average on June 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 26, 2026. You may want to consider a long position or call options on AMRX as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AMRX just turned positive on May 27, 2026. Looking at past instances where AMRX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
AMRX moved above its 50-day moving average on June 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRX advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 253 cases where AMRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 17 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMRX broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (105.263) is normal, around the industry mean (79.619). P/E Ratio (43.541) is within average values for comparable stocks, (97.743). AMRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (1.724) is also within normal values, averaging (96.439).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsGeneric
Advertisement